Preclinical Large-Vessel Occlusion Stroke Research Services

Large-vessel occlusion (LVO) accounts for up to 38% of cases of acute ischemic stroke. It is typically characterized by occlusion of proximal vessels, including the internal carotid artery, as well as the proximal anterior, middle, and posterior cerebral arteries, the intracranial vertebral artery, and the basilar artery. The primary treatment strategy for LVO stroke is mechanical thrombectomy (MT) performed alone or in combination with intravenous thrombolysis (IVT). However, the use of this approach is limited. Thus, therefore, future studies are needed to further elucidate the pathophysiology of fast and slow progressors of acute LVO and provide new opportunities for successful translation of neuroprotective therapies.

Fig. 1 LVO Stroke secondary to intracranial atherosclerotic disease: identification, medical and interventional treatment, and outcomes. (De Havenon, et al., 2023)

Ace Therapeutics has extensive experience in preclinical LVO stroke research. We are committed to helping our clients understand the pathomechanisms of this complex disease and to supporting the development of novel therapeutics.

Custom In Vitro Neurovascular Models of LVO

We offer reliable in vitro neurovascular models of LVOs causing acute ischemic stroke, including primary neuronal cultures derived from rodent brain tissue and variations of multicellular cocultures. These models allow us to help our clients screen neuroprotective agents and perform preclinical testing of innovative therapeutics.

Custom Animal Models of LVO Stroke

At Ace Therapeutics, we are dedicated to advancing the understanding of LVO stroke through the use of both small animal models (such as mice and rats) and large animal models (including dogs and non-human primates) tailored specifically for this purpose. We can help clients select reliable in vivo models of LVO stroke based on what outcomes are being assessed and the cross-reactivity of the potential therapeutic in the desired preclinical model.

Types of Drugs We Can Develop for LVO Stroke

Preclinical Evaluation of LVO Stroke Therapies

Preclinical Imaging Services for LVO Stroke Therapy Development

• Our experts combine diffusion-weighted magnetic resonance imaging (MRI) and perfusion imaging to longitudinally image the core and penumbra in LVO stroke models, which can provide information on the location of neuronal swelling and cell death processes as well as the location of inadequate tissue perfusion. We also use MRI to image the metabolic activity of ischemic tissue, monitoring the transition to anaerobic metabolism.
• Histological Evaluation of Ischemic Brain
• We provide histological staining with hematoxylin and eosin to evaluate ischemic brain lesions in animal models of LVO. Additionally, we help clients assess the integrity of the blood-brain barrier (BBB) before and after drug administration by immunostaining for immunoglobulins.

Behavioral Testing in Animal Models of LVO Stroke

We employ neurological deficit scores to measure functional outcomes in animal models of LVO stroke. We also provide behavior task tests to evaluate the efficacy of therapeutics for LVO stroke, including the rotarod rest.

At Ace Therapeutics, collaboration is critical to advancing preclinical studies in LVO stroke. By building strong partnerships, we strive to advance your understanding of this disease and develop effective strategies to support your research. Contact us to accelerate your next breakthrough.

1. Keister, A., et al. (2023). Preclinical Models of Large-Vessel Occlusion Stroke. Stroke: Vascular and Interventional Neurology, e000604.
2. De Havenon, A., et al. (2023). Large vessel occlusion stroke due to intracranial atherosclerotic disease: identification, medical and interventional treatment, and outcomes. Stroke, 54(6), 1695-1705.

• Preclinical Lacunar Stroke Research Services